APHY - Assured Pharmacy Reports Results for the Fiscal

New Post Public Reply Private Reply Replies (0) Message Board
SevenTenEleven

APHY - Assured Pharmacy Reports Results for the Fiscal Year 2011 

Wednesday 4 April 2012 


Assured Pharmacy (APHY: pinksheets), a leading specialty pharmacy group providing prescription medications to sufferers of chronic pain, announced net sales of $16,444,573 for the year ended December 31, 2011, an increase of $167,821 or 1.0%, from $16,276,752 for the year ended December 31, 2010. Basic and diluted net loss per share was $1.14 for the year 2011, a 54.0% improvement compared to $2.48 net loss per share in the same period in 2010. 

The increase in sales for the year 2011 compared to the year 2010 was primarily due to an increase in the number of patients serviced as a result of our continued direct sales efforts and to a much lesser extent the opening of our 5th pharmacy in the Kansas City metropolitan area in November 2011. The increase in revenue from increased patients was partially offset by a decrease in revenue per prescription due to increased generic utilization by our patients and to a lesser extent a decrease in management service fee revenue of $160,005. As a result of the increase in generic utilization, our gross profit margins on pharmacy revenue increased to 19.1% for the year 2011 up from 17.6% for the year 2010. The number of prescriptions filled by our pharmacies increased by 6,300 prescriptions or 5.7%, with 117,410 prescriptions filled in the year ended December 31, 2011, as compared to 111,110 prescriptions filled in the year 2010. 

We are pleased with the year over year performance improvement in our operations for the year 2011 and the opening our new pharmacy in Kansas. The opening of our new pharmacy and improved operating results reflect continued progress in the implementation of our strategies and provide further validation of our business model as we move forward with the expansion of our business," said Robert DelVecchio, Chief Executive Officer of Assured Pharmacy. 

The audited financial statements for the years ended December 31, 2011, and 2010 have been posted on the OTC Markets website and are available at www.otcmarkets.com under our trading symbol, APHY. 

About Assured Pharmacy, Inc. 

Assured Pharmacy, Inc. is a growing provider of specialty pharmacy services to patients and physicians in the treatment of chronic pain. Through its network of specialty pharmacies, the Company predominantly dispenses highly regulate pain mediations to sufferers of chronic pain, while stringently adhering to federal and state reporting requirements for both patients and physicians. The Company derives its revenue primarily from the sale of prescription drugs and does not keep in inventory non-prescription drugs or health and beauty related products inventoried at traditional pharmacies. The majority of the Company's business is derived from repeat visits from its customer base of physician-referred chronic pain patients. "Walk-in" prescriptions from physicians are limited. The Company currently has five operating pharmacies which are wholly owned including its fifth operating pharmacy in the Kansas City metropolitan area which opened in November 2011. 

Safe Harbor Statement 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. These forward-looking statements are based largely on the expectations or forecasts of future events, can be affected by inaccurate assumptions, and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the control of management. Therefore, actual results could differ materially from the forward-looking statements contained in this press release. A wide variety of factors that may cause actual results to differ from the forward-looking statements include, but are not limited to, the following: the Company's ability to increase revenue and profits in the current economic climate; the effect of changing economic conditions; lack of sufficient financing for opening new pharmacies; inability to manage growth; and changes in government regulations, controls and similar matters. These cautionary statements should not be construed as exhaustive or as any admission as to the adequacy of the Company's disclosures. The Company cannot predict or determine after the fact what factors would cause actual results to differ materially from those indicated by the forward-looking statements or other statements. The reader should consider statements that include the words "believes," "expects," "anticipates," "intends," "estimates," "plans," "projects," "should," or other expressions that are predictions of or indicate future events or trends, to be uncertain and forward-looking. The Company does not undertake to publicly update or revise forward-looking statements, whether as a result of new information, future events or otherwise. 

Investor Contact: 

Erika Moran/Adam Holdsworth 
The Investor Relations Group 
11 Stone St. 3rd Floor 
New York, NY 
212-825-3210 
SOURCE Assured Pharmacy, Inc.

Assured Pharmacy, Inc. (APHYQ) Stock Research Links

APHYQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 176

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading
Taiwan Fuses Ancient TCM with Modern Bio Tech in 2026

Updated Category News Views 188

The Dynamic Fusion of Heritage and Innovation When you think about it, mixing centuries-old herbal wisdom with today's cutting-edge biotech might sound like a plot twist, but that's exactly what's cooking in Taiwan. Over at SupplySide Global 2026 in Las Vegas, Taiwan's got something more than just traditional medicine to flaunt; it's showcasing an impressive fusion of...

Continue Reading
Alaska's Insurance Maze: Coverage Over Cheap Policies

Updated Category News Views 138

Beyond Premiums: Assessing Real Coverage Needs The Alaskan wilderness isn't just home to stunning views; it's also a land where insurance needs to go beyond the average cookie-cutter policy. You'd think the cheapest option would suffice, but that's where residents might trip into financial quicksand. Devery Prince, a seasoned insurance principal, sheds light on why...

Continue Reading
Aluminum Design Fumble: Geometry Over Wall Thickness

Updated Category News Views 218

A Misstep in Aluminum Design Practices Well, here's a nugget of wisdom for the metal enthusiasts out there—stop beefing up aluminum components with thicker walls and focus on smart geometry. This isn't a drill, folks. Mark Coyle, a seasoned mind over at American Custom Metals, has been waving the flag for smarter aluminum design methods right from Rochester, NY, and...

Continue Reading
Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 375

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading
Survivors Secure $800M Settlement with NY Archdiocese

Updated Category News Views 178

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 92

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
DIRECTV Bags New NHL Deals: Stakes for Sports Fans

Updated Category News Views 229

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Continue Reading
ASTS Faces Crucial Deadline Amidst Legal Turmoil

Updated Category News Views 169

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 237

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading

Top 5 Most Recently Viewed Articles

Oasis Management Proposes Governance Change for Kobayashi Pharma

Updated Category News Views 243

Oasis Management Advocates for Enhanced Governance at Kobayashi Pharma Oasis Management Company Ltd. (“Oasis”) has emerged as a significant voice among shareholders of Kobayashi Pharmaceutical Co., Ltd. (4967 JT). Holding over 7.5% of the company, Oasis is actively pushing for essential changes in leadership and independent oversight to address pressing governance...

Continue Reading
Synopsys Faces Legal Challenges Amid Stockholder Concerns

Updated Category News Views 235

Understanding the Recent Class Action Lawsuit Against Synopsys Recently, concerns have emerged regarding Synopsys, Inc. as a class action lawsuit was filed alleging serious misrepresentations concerning the company’s financial health. Investors who have been affected are encouraged to seek guidance to explore their legal rights and options that may arise from this...

Continue Reading
Cumulus Media's Engaging Coverage of 2025 NCAA Basketball Events

Updated Category News Views 228

Thrilling NCAA Basketball Coverage by Cumulus Media Cumulus Media’s Westwood One is gearing up for an exciting audio experience during the 2025 NCAA Men’s and Women’s Basketball tournaments. With the largest radio network in the country, Westwood One will deliver comprehensive coverage that connects die-hard sports fans across a plethora of platforms. Connecting...

Continue Reading
ByteDance's Ambitious AI Chip Investment Plans for 2025

Updated Category News Views 1644

ByteDance's Strategic Investment in AI Technology ByteDance, the renowned owner of TikTok, is making significant strides in artificial intelligence by planning to invest more than $12 billion on AI infrastructure in the upcoming years. This ambitious investment highlights the company's commitment to harnessing cutting-edge technology for growth. According to reports, the...

Continue Reading
Investors of ModivCare, Inc. Urged to Join Class Action Lawsuit

Updated Category News Views 130

Investors of ModivCare, Inc. Urged to Join Class Action Lawsuit The law firm Robbins Geller Rudman & Dowd LLP is calling for investors of ModivCare, Inc. (NASDAQ: MODV) who have experienced significant financial losses to take action. Understanding the Class Action Lawsuit The upcoming class action lawsuit, titled Kalera v. ModivCare, Inc., brings serious allegations...

Continue Reading